Challenges in Real-Time Testing of Biosimilars

Key Challenges in Real-Time Stability Testing of Biosimilars

Biosimilars, as complex biological products, pose unique challenges in stability testing — particularly under real-time conditions. Unlike small-molecule generics, biosimilars must demonstrate not only chemical stability but also consistent biological activity, structural integrity, and immunogenicity profile over time. Real-time stability testing of biosimilars must therefore be meticulously planned and rigorously executed to meet global regulatory standards. This article provides a detailed look at the most common challenges and strategies to overcome them in biosimilar real-time testing.

1. Why Real-Time Stability Testing Is Critical for Biosimilars

Real-time stability testing validates the proposed shelf life of biosimilars under recommended storage conditions (e.g., 2–8°C). Since biosimilars are administered parenterally and often stored under cold-chain conditions, real-time data is essential to ensure product safety and efficacy throughout the product lifecycle.

Importance of Real-Time Data for Biosimilars:

Supports comparability with the reference biologic
Demonstrates consistent biological activity over shelf life
Provides insight into degradation patterns unique to biologics
Addresses regulatory scrutiny for immunogenicity and potency loss

2. Unique Degradation Pathways in Biosimilars

Biosimilars are sensitive to multiple degradation mechanisms not typically observed in small molecules. Real-time testing must account for these pathways under intended storage conditions.

Common Degradation Mechanisms:

Protein aggregation: Can

lead to loss of activity or increased immunogenicity

Deamidation and oxidation: Resulting in structural and functional changes

Fragmentation: Loss of terminal sequences or cleavage at weak bonds

Denaturation: From temperature excursions or pH shifts

Real-time testing provides a more accurate picture of how these changes progress under actual storage scenarios compared to accelerated conditions.

3. Regulatory Expectations for Biosimilar Stability

Major regulatory bodies have laid out specific guidance for biosimilar stability testing. These include requirements beyond standard ICH Q1A(R2), such as functional assays and advanced analytical techniques.

Agency Requirements:

EMA: Requires comparability over shelf life using orthogonal analytical methods
FDA: Emphasizes real-time, real-condition testing with full characterization at expiry
WHO TRS 977: Provides detailed expectations for biosimilar long-term and post-approval stability

Minimum Study Requirements:

Real-time data for at least one batch at proposed storage condition
Functional bioassays to confirm potency
Testing in final container-closure system
Inclusion of reference biologic as control (optional but recommended)

4. Key Challenges in Real-Time Testing of Biosimilars

A. Cold Chain Management

Maintaining 2–8°C conditions consistently over 24–36 months is resource intensive
Chamber validation must simulate commercial cold-chain logistics
Temperature excursions must be evaluated and documented

B. Complex Analytical Methods

Real-time testing requires highly sensitive and validated methods
Bioassays (e.g., cell-based assays, ELISA) must remain reproducible across time points
Structural techniques like CD spectroscopy and SEC must be calibrated regularly

C. Immunogenicity Monitoring

Aggregates and fragments may increase over time, posing safety risks
No single test detects all immunogenicity risks — requires a battery of assays

D. Reference Product Benchmarking

Maintaining consistency with the innovator’s stability profile is complex
Batch-to-batch variability of the reference product can obscure comparability

E. High Cost and Long Duration

Storage, testing, and data validation over 2–3 years is expensive
Delays in data collection may push regulatory submission timelines

5. Designing an Effective Real-Time Stability Study for Biosimilars

Recommended Study Design:

Storage Conditions: 2–8°C with excursion testing (e.g., 25°C/60% RH for 24 hours)
Pull Points: 0, 3, 6, 9, 12, 18, 24, 30, and 36 months
Parameters: Appearance, pH, bioassay, aggregates, sub-visible particles, potency, charge variants
Batch Inclusion: At least three commercial-scale batches with representative packaging

Include reference product where feasible for direct trend comparison.

6. Analytical Techniques Essential in Biosimilar Stability Testing

In addition to standard ICH Q1A(R2) testing parameters, biosimilar real-time stability should include:

Functional and Structural Tests:

Potency bioassays (e.g., receptor binding, signal transduction)
Size-exclusion chromatography (SEC) for aggregation
Capillary electrophoresis (CE-SDS) for purity and fragmentation
Isoelectric focusing (IEF) or cIEF for charge variants
Dynamic light scattering (DLS) for particle sizing

Each assay must be validated for precision, sensitivity, and specificity.

7. Case Study: Real-Time Stability Testing of a Monoclonal Antibody Biosimilar

A biosimilar mAb intended for oncology indications was subjected to a 36-month real-time stability study at 2–8°C. Pull-point testing included SEC, cIEF, ELISA-based bioassay, and CE-SDS. At 18 months, a trend in aggregate growth (>2%) triggered a CAPA. Investigation revealed increased agitation sensitivity in the new stopper system. The manufacturer switched to a different closure with lower frictional force and resumed testing. The final data package, with updated packaging, supported a 24-month shelf life and was approved by EMA and WHO.

8. Regulatory Submission and Documentation Tips

Where to Include in the CTD:

Module 3.2.S.7.1: Drug substance stability including aggregation and degradation
Module 3.2.P.8.1: Drug product stability summary
Module 3.2.P.8.3: Supporting data tables with graphs and interpretation

Best Practices:

Include justification for each parameter tested
Discuss any deviations and CAPA taken
Use trend analysis and predictive modeling to support shelf-life extrapolation

9. Tools and Resources for Biosimilar Real-Time Stability

For biosimilar developers, the following resources are invaluable:

WHO biosimilar TRS 1004 and 977 guidance documents
EMA Biosimilar Guideline on Quality of Biological Medicinal Products
Validated real-time stability protocol templates for biosimilars
SOPs for aggregation and immunogenicity tracking
Stability chamber qualification reports for 2–8°C range

Templates and case study data can be downloaded from Pharma SOP. Visit Stability Studies for more biosimilar-specific real-time stability planning guides.

Conclusion

Real-time stability testing of biosimilars is a complex but essential process that ensures product safety, regulatory acceptance, and therapeutic equivalence with the innovator. From managing sensitive degradation pathways to complying with stringent analytical and regulatory expectations, biosimilar developers must approach stability studies with a well-structured and scientifically rigorous mindset. When done right, real-time stability not only validates shelf life but also builds confidence among regulators, prescribers, and patients in the biosimilar product.